Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009

Abstract:
OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today the publication of its Annual Report 2008.

OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009

The Netherlands | Posted on March 30th, 2009

During the year 2008, OctoPlus adapted its strategy to utilise its proprietary drug delivery technology for the controlled release of injectable products, in particular proteins, on behalf of a growing client base. The main product based on this technology, LocteronŽ, is moving into clinical Phase IIb this year. In 2008, OctoPlus worked on five projects to evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology, and the Company aims to sign six more in 2009. Together with the anticipated growth in our Contract Development services we expect to be able to achieve a positive cashflow at the operational level for the year 2009.

The Annual Report is available on the Company's website, www.octoplus.nl. Hard copies of the report can be requested by sending an e-mail to

Annual General Meeting of Shareholders
The Annual General Meeting of Shareholders (AGM) will take place at the Company's headquarters in Leiden on 23 April 2009 at 14:00 Central European Time (CET). The agenda and other information regarding the AGM will be published on 8 April 2009 via the Company's website.

For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, e-mail

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The lead product incorporating our technology is LocteronŽ, a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

Copyright © OctoPlus

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Scientists discover new 'boat' form of promising semiconductor: GeSe Uncommon form attenuates semiconductor's band gap size March 23rd, 2017

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

Rare-earths become water-repellent only as they age March 22nd, 2017

Nanomedicine

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Biophysicists propose new approach for membrane protein crystallization March 8th, 2017

Announcements

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Scientists discover new 'boat' form of promising semiconductor: GeSe Uncommon form attenuates semiconductor's band gap size March 23rd, 2017

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

Rare-earths become water-repellent only as they age March 22nd, 2017

Financial Reports

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Nanobiotechnology

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Biophysicists propose new approach for membrane protein crystallization March 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project